Cholecystectomy

Series

Gastrointestinal

Status

Published

Date

15 Jan 2021

Number of report

066

Ask the expert

Report overview
Table of content
Newsfeed
Ask the expert

The report presents a summary of reimbursement situation for cholecystectomy in Europe.

Sample pages are provided for an older version of the report. Before delivery to the client, the report is updated to the current state (e.g., 2022 coding, tariffs, and policy considerations).

Procedure codes for open and laparoscopic cholecystectomy will be provided in the analysis.

The following indications will be considered:

calculus of gallbladder with acute cholecystitis;
acute cholecystitis.

The only reimbursement within public / statutory health insurance systems is considered. The results will be provided for hospital settings and day case

Report includes essential information about reimbursement and national funding, including:

Brief overview of reimbursement system for medical devices
Procedure coding for technology
Diagnosis coding
Payment mechanism for technology
Reimbursement tariffs for technology
Restrictions in indications or scenarios for use of technology
Policy considerations by payers and policy-makers about technology

Reimbursement information is provided for the following geographies:

Austria
Belgium
Denmark
England (UK)
France
Germany
Italy
Netherlands
Norway
Sweden
Switzerland

It is possible to order analysis only for individual countries and add procedure volume data.

Table of content is not available at the moment. Report is still ongoing.

28

Apr 2022

In March 2022, the National Institute for Health and Care Excellence (NICE) published five new Interventional Procedure Guidance (endoscopic balloon dilation for subglottic or tracheal stenosis, intramedullary distraction for lower limb lengthening, endoscopic full thickness removal of gastrointestinal stromal tumors of the stomach, percutaneous insertion of a cystic duct stent after cholecystostomy, and liposuction for chronic lipoedema), four new Medical Technologies Guidance (myCOPD, UroShield, Prontosan for wounds, and 3C Patch for diabetic foot ulcers), one new Diagnostic Guidance (terminated assessment of Freelite assays for multiple myeloma), and six new Medtech Innovation Briefings (Genedrive MT-RNR1 ID System, icobrain for multiple sclerosis, Al for analyzing chest X-ray images, and others). Also, three new clinical guidelines were published, and six were updated.